If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ARCHIVE<br /> VOLUME 111 NUMBER 1 JANUARY 2016<br /> www.nature.com/ajg<br /> official publication of the american college of gastroenterology<br /> LEADING ARTICLES OF THE MONTH<br /> The Red Section: EndoTech Update<br /> 6 Just Clip It: Endoscopic Clipping in the 21st Century<br /> B. Joseph Elmunzer<br /> Practice Guidelines<br /> 30 ACG Clinical Guideline: Diagnosis and Management of Barrett’s<br /> Esophagus CME<br /> N.J. Shaheen, G.W. Falk, P.G. Iyer and L.B. Gerson<br /> Clinical and Systematic Reviews<br /> 53 Diagnosis and Management of Functional Heartburn CME<br /> C. Hachem and N.J. Shaheen<br /> Endoscopy<br /> 63 Effect of Dynamic Position Changes on Adenoma Detection during<br /> Colonoscope Withdrawal: A Randomized Controlled Multicenter Trial<br /> S.-W. Lee, J.H. Chang, J.-S. Ji et al.<br /> Liver<br /> 78 Diagnosis of Minima<a title="AJG_Vol.112.No1 page 1" href="http://viewer.zmags.com/publication/f9bebf6b?page=1"> ARCHIVE VOLUME 111 NUMBER 1 JANUARY 2016 www.nat</a> <a title="AJG_Vol.112.No1 page 2" href="http://viewer.zmags.com/publication/f9bebf6b?page=2"> VOLUME 112 NUMBER 1 JANUARY 2017 www.nature.com/a</a> <a title="AJG_Vol.112.No1 page 3" href="http://viewer.zmags.com/publication/f9bebf6b?page=3"> VEMLIDY is a novel, targeted prodrug of tenofovir</a> <a title="AJG_Vol.112.No1 page 4" href="http://viewer.zmags.com/publication/f9bebf6b?page=4"> NOW AVAILABLE FOR THE TREATMENT OF CHRONIC HEPATI</a> <a title="AJG_Vol.112.No1 page 5" href="http://viewer.zmags.com/publication/f9bebf6b?page=5"> VEMLIDY® (tenofovir alafenamide 25mg) tablets, fo</a> <a title="AJG_Vol.112.No1 page 6" href="http://viewer.zmags.com/publication/f9bebf6b?page=6"> Laboratory Abnormalities: Laboratory abnormalitie</a> <a title="AJG_Vol.112.No1 page 7" href="http://viewer.zmags.com/publication/f9bebf6b?page=7"> www.nature.com/ajg The American Journal o</a> <a title="AJG_Vol.112.No1 page 8" href="http://viewer.zmags.com/publication/f9bebf6b?page=8"> FOR PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERA</a> <a title="AJG_Vol.112.No1 page 9" href="http://viewer.zmags.com/publication/f9bebf6b?page=9"> BRIEF SUMMARY OF PRESCRIBING INFORMATION This bri</a> <a title="AJG_Vol.112.No1 page 10" href="http://viewer.zmags.com/publication/f9bebf6b?page=10"> American College of Gastroenterology & World Gast</a> <a title="AJG_Vol.112.No1 page 11" href="http://viewer.zmags.com/publication/f9bebf6b?page=11"> official publication of the american college</a> <a title="AJG_Vol.112.No1 page 12" href="http://viewer.zmags.com/publication/f9bebf6b?page=12"> Multidisciplinary Approach to the Diagnosis and M</a> <a title="AJG_Vol.112.No1 page 13" href="http://viewer.zmags.com/publication/f9bebf6b?page=13"> Attend an ACG Regional Postgraduate Course 2017 W</a> <a title="AJG_Vol.112.No1 page 14" href="http://viewer.zmags.com/publication/f9bebf6b?page=14"> Tissue microarrays stained for MUC5AC expression </a> <a title="AJG_Vol.112.No1 page 15" href="http://viewer.zmags.com/publication/f9bebf6b?page=15"> CONTENTS 1.0 0.8 0.6 Cumulative sur</a> <a title="AJG_Vol.112.No1 page 16" href="http://viewer.zmags.com/publication/f9bebf6b?page=16"> www.nature.com/ajg </a> <a title="AJG_Vol.112.No1 page 17" href="http://viewer.zmags.com/publication/f9bebf6b?page=17"> GI�QUALITY�IMPROVEMENT�CONSORTIUM��LTD� 3 Se�ing</a> <a title="AJG_Vol.112.No1 page 18" href="http://viewer.zmags.com/publication/f9bebf6b?page=18"> A CURE FOR EVERY TYPE Patients of any HCV genotyp</a> <a title="AJG_Vol.112.No1 page 19" href="http://viewer.zmags.com/publication/f9bebf6b?page=19"> Albert Einstein used with permission of the HUJ/G</a> <a title="AJG_Vol.112.No1 page 20" href="http://viewer.zmags.com/publication/f9bebf6b?page=20"> THE FIRST AND ONLY PAN-GENOTYPIC ONCE-DAILY SINGL</a> <a title="AJG_Vol.112.No1 page 21" href="http://viewer.zmags.com/publication/f9bebf6b?page=21"> HARVONI® (ledipasvir 90 mg and sofosbuvir 400 mg)</a> <a title="AJG_Vol.112.No1 page 22" href="http://viewer.zmags.com/publication/f9bebf6b?page=22"> Brief Summary (cont.) Postmarketing Experience: B</a> <a title="AJG_Vol.112.No1 page 23" href="http://viewer.zmags.com/publication/f9bebf6b?page=23"> EPCLUSA® (sofosbuvir 400 mg and velpatasvir 100 m</a> <a title="AJG_Vol.112.No1 page 24" href="http://viewer.zmags.com/publication/f9bebf6b?page=24"> Brief Summary (cont.) DRUG INTERACTIONS: Sofosbuv</a> <a title="AJG_Vol.112.No1 page 25" href="http://viewer.zmags.com/publication/f9bebf6b?page=25"> Want to discover the right jobseekers? Recruit t</a> <a title="AJG_Vol.112.No1 page 26" href="http://viewer.zmags.com/publication/f9bebf6b?page=26"> ANNOUNCING CCFA’S Visiting IBD Fellow Program Th</a> <a title="AJG_Vol.112.No1 page 27" href="http://viewer.zmags.com/publication/f9bebf6b?page=27"> RECOMMEND THE MOST POWERFUL OTC PPI FROM THE STAR</a> <a title="AJG_Vol.112.No1 page 28" href="http://viewer.zmags.com/publication/f9bebf6b?page=28"> THE RED SECTION 1 see related editori</a> <a title="AJG_Vol.112.No1 page 29" href="http://viewer.zmags.com/publication/f9bebf6b?page=29"> 2 THE RED SECTION Hepatitis School h</a> <a title="AJG_Vol.112.No1 page 30" href="http://viewer.zmags.com/publication/f9bebf6b?page=30"> The first concept is that “if you haven't serve</a> <a title="AJG_Vol.112.No1 page 31" href="http://viewer.zmags.com/publication/f9bebf6b?page=31"> 4 THE RED SECTION ENDOTECH UPDATE WHAT IS IMP</a> <a title="AJG_Vol.112.No1 page 32" href="http://viewer.zmags.com/publication/f9bebf6b?page=32"> a 10 cm Endoscope Distances</a> <a title="AJG_Vol.112.No1 page 33" href="http://viewer.zmags.com/publication/f9bebf6b?page=33"> 6 THE RED SECTION 10,000 7,500 </a> <a title="AJG_Vol.112.No1 page 34" href="http://viewer.zmags.com/publication/f9bebf6b?page=34"> potential cost savings. Finally, it may also be e</a> <a title="AJG_Vol.112.No1 page 35" href="http://viewer.zmags.com/publication/f9bebf6b?page=35"> 8 THE RED SECTION HOW I APPROACH IT PARTICIPA</a> <a title="AJG_Vol.112.No1 page 36" href="http://viewer.zmags.com/publication/f9bebf6b?page=36"> Table 1. Components of the screening program (1) </a> <a title="AJG_Vol.112.No1 page 37" href="http://viewer.zmags.com/publication/f9bebf6b?page=37"> 10 THE RED SECTION CONCLUSIONS Despite a</a> <a title="AJG_Vol.112.No1 page 38" href="http://viewer.zmags.com/publication/f9bebf6b?page=38"> THE RED SECTION 11 see related editori</a> <a title="AJG_Vol.112.No1 page 39" href="http://viewer.zmags.com/publication/f9bebf6b?page=39"> 12 THE RED SECTION The cecum is insuf</a> <a title="AJG_Vol.112.No1 page 40" href="http://viewer.zmags.com/publication/f9bebf6b?page=40"> Springer Nature </a> <a title="AJG_Vol.112.No1 page 41" href="http://viewer.zmags.com/publication/f9bebf6b?page=41"> 14 THE RED SECTION A Large Hemispherical C</a> <a title="AJG_Vol.112.No1 page 42" href="http://viewer.zmags.com/publication/f9bebf6b?page=42"> THE RED SECTION 15 Endoscopic Removal of S</a> <a title="AJG_Vol.112.No1 page 43" href="http://viewer.zmags.com/publication/f9bebf6b?page=43"> 16 THE RED SECTION Video of the Month End</a> <a title="AJG_Vol.112.No1 page 44" href="http://viewer.zmags.com/publication/f9bebf6b?page=44"> PRACTICE GUIDELINES 17 CME Continui</a> <a title="AJG_Vol.112.No1 page 45" href="http://viewer.zmags.com/publication/f9bebf6b?page=45"> 18 PRACTICE GUIDELINES CME ACG Clinic</a> <a title="AJG_Vol.112.No1 page 46" href="http://viewer.zmags.com/publication/f9bebf6b?page=46"> Evaluation of Abnormal Liver Tests 19 Ta</a> <a title="AJG_Vol.112.No1 page 47" href="http://viewer.zmags.com/publication/f9bebf6b?page=47"> 20 Kwo et al. to as liver chemistries </a> <a title="AJG_Vol.112.No1 page 48" href="http://viewer.zmags.com/publication/f9bebf6b?page=48"> blood and measures factors 1, 2, 5, 7, 9, and 10.</a> <a title="AJG_Vol.112.No1 page 49" href="http://viewer.zmags.com/publication/f9bebf6b?page=49"> 22 Kwo et al. Table 2. Summary of studi</a> <a title="AJG_Vol.112.No1 page 50" href="http://viewer.zmags.com/publication/f9bebf6b?page=50"> found that 9% of hepatitis C patients with normal</a> <a title="AJG_Vol.112.No1 page 51" href="http://viewer.zmags.com/publication/f9bebf6b?page=51"> 24 Kwo et al. and the potential for pr</a> <a title="AJG_Vol.112.No1 page 52" href="http://viewer.zmags.com/publication/f9bebf6b?page=52"> and may include hepatosplenomegaly, abnormal live</a> <a title="AJG_Vol.112.No1 page 53" href="http://viewer.zmags.com/publication/f9bebf6b?page=53"> 26 Kwo et al. helpful in this circumst</a> <a title="AJG_Vol.112.No1 page 54" href="http://viewer.zmags.com/publication/f9bebf6b?page=54"> Before initiation of evaluation of abnormal liv</a> <a title="AJG_Vol.112.No1 page 55" href="http://viewer.zmags.com/publication/f9bebf6b?page=55"> 28 Kwo et al. liver edge due to cirrho</a> <a title="AJG_Vol.112.No1 page 56" href="http://viewer.zmags.com/publication/f9bebf6b?page=56"> elevation as 2–5X ULN, moderate AST and/or</a> <a title="AJG_Vol.112.No1 page 57" href="http://viewer.zmags.com/publication/f9bebf6b?page=57"> 30 Kwo et al. Table 5. Causes of elevat</a> <a title="AJG_Vol.112.No1 page 58" href="http://viewer.zmags.com/publication/f9bebf6b?page=58"> should be considered, including PBC, PSC, and dru</a> <a title="AJG_Vol.112.No1 page 59" href="http://viewer.zmags.com/publication/f9bebf6b?page=59"> 32 Kwo et al. Table 6. Causes of elevat</a> <a title="AJG_Vol.112.No1 page 60" href="http://viewer.zmags.com/publication/f9bebf6b?page=60"> Elevated total bilirubin (predominant unconj</a> <a title="AJG_Vol.112.No1 page 61" href="http://viewer.zmags.com/publication/f9bebf6b?page=61"> 34 Kwo et al. with elevated conjugated</a> <a title="AJG_Vol.112.No1 page 62" href="http://viewer.zmags.com/publication/f9bebf6b?page=62"> 45. Weinbaum CM, Williams I, Mast EE et al. Recom</a> <a title="AJG_Vol.112.No1 page 63" href="http://viewer.zmags.com/publication/f9bebf6b?page=63"> 36 PRACTICE GUIDELINES CME Continui</a> <a title="AJG_Vol.112.No1 page 64" href="http://viewer.zmags.com/publication/f9bebf6b?page=64"> PRACTICE GUIDELINES 37 Recommendat</a> <a title="AJG_Vol.112.No1 page 65" href="http://viewer.zmags.com/publication/f9bebf6b?page=65"> 38 Robertson et al. FIT-based screenin</a> <a title="AJG_Vol.112.No1 page 66" href="http://viewer.zmags.com/publication/f9bebf6b?page=66"> Recommendations on Fecal Immunochemical Testing </a> <a title="AJG_Vol.112.No1 page 67" href="http://viewer.zmags.com/publication/f9bebf6b?page=67"> 40 Robertson et al. Table 2. Sensitivit</a> <a title="AJG_Vol.112.No1 page 68" href="http://viewer.zmags.com/publication/f9bebf6b?page=68"> Recommendations on Fecal Immunochemical Testing </a> <a title="AJG_Vol.112.No1 page 69" href="http://viewer.zmags.com/publication/f9bebf6b?page=69"> 42 Robertson et al. Table 4. FIT v gFOBT</a> <a title="AJG_Vol.112.No1 page 70" href="http://viewer.zmags.com/publication/f9bebf6b?page=70"> review (63). Both meta-analyses found participati</a> <a title="AJG_Vol.112.No1 page 71" href="http://viewer.zmags.com/publication/f9bebf6b?page=71"> 44 Robertson et al. Table 5. FIT vs. FS </a> <a title="AJG_Vol.112.No1 page 72" href="http://viewer.zmags.com/publication/f9bebf6b?page=72"> Recommendations on Fecal Immunochemical Testing </a> <a title="AJG_Vol.112.No1 page 73" href="http://viewer.zmags.com/publication/f9bebf6b?page=73"> 46 Robertson et al. Table 7. Summary of </a> <a title="AJG_Vol.112.No1 page 74" href="http://viewer.zmags.com/publication/f9bebf6b?page=74"> simulation modeling analysis using a quantitative</a> <a title="AJG_Vol.112.No1 page 75" href="http://viewer.zmags.com/publication/f9bebf6b?page=75"> 48 Robertson et al. The Task Force </a> <a title="AJG_Vol.112.No1 page 76" href="http://viewer.zmags.com/publication/f9bebf6b?page=76"> cut-off value, 30 mg hgb/g feces). Positivity was</a> <a title="AJG_Vol.112.No1 page 77" href="http://viewer.zmags.com/publication/f9bebf6b?page=77"> 50 Robertson et al. </a> <a title="AJG_Vol.112.No1 page 78" href="http://viewer.zmags.com/publication/f9bebf6b?page=78"> 8. Songster CL, Barrows GH, Jarrett DD. Immunoch</a> <a title="AJG_Vol.112.No1 page 79" href="http://viewer.zmags.com/publication/f9bebf6b?page=79"> 52 Robertson et al. 55. van Rossum LG, </a> <a title="AJG_Vol.112.No1 page 80" href="http://viewer.zmags.com/publication/f9bebf6b?page=80"> from a nested in a cohort case-control s</a> <a title="AJG_Vol.112.No1 page 81" href="http://viewer.zmags.com/publication/f9bebf6b?page=81"> 54 CLINICAL AND SYSTEMATIC REVIEWS REVIEW see</a> <a title="AJG_Vol.112.No1 page 82" href="http://viewer.zmags.com/publication/f9bebf6b?page=82"> as this limits assessment of histologic risk fact</a> <a title="AJG_Vol.112.No1 page 83" href="http://viewer.zmags.com/publication/f9bebf6b?page=83"> 56 Backes et al. REVIEW and specificity th</a> <a title="AJG_Vol.112.No1 page 84" href="http://viewer.zmags.com/publication/f9bebf6b?page=84"> Optical Diagnosis of T1 Colorectal Cancer 57 </a> <a title="AJG_Vol.112.No1 page 85" href="http://viewer.zmags.com/publication/f9bebf6b?page=85"> 58 Backes et al. REVIEW Optical diagnosis </a> <a title="AJG_Vol.112.No1 page 86" href="http://viewer.zmags.com/publication/f9bebf6b?page=86"> Optical Diagnosis of T1 Colorectal Cancer 59 </a> <a title="AJG_Vol.112.No1 page 87" href="http://viewer.zmags.com/publication/f9bebf6b?page=87"> 60 Backes et al. a1 </a> <a title="AJG_Vol.112.No1 page 88" href="http://viewer.zmags.com/publication/f9bebf6b?page=88"> Optical Diagnosis of T1 Colorectal Cancer 61 </a> <a title="AJG_Vol.112.No1 page 89" href="http://viewer.zmags.com/publication/f9bebf6b?page=89"> 62 Backes et al. Table 5. imaging, Impl</a> <a title="AJG_Vol.112.No1 page 90" href="http://viewer.zmags.com/publication/f9bebf6b?page=90"> colorectal lesions and stratifying patient</a> <a title="AJG_Vol.112.No1 page 91" href="http://viewer.zmags.com/publication/f9bebf6b?page=91"> 64 Backes et al. REVIEW 57. Rastogi A, Rao</a> <a title="AJG_Vol.112.No1 page 92" href="http://viewer.zmags.com/publication/f9bebf6b?page=92"> CLINICAL AND SYSTEMATIC REVIEWS 65 see</a> <a title="AJG_Vol.112.No1 page 93" href="http://viewer.zmags.com/publication/f9bebf6b?page=93"> 66 Irvine et al. REVIEW damage to the smal</a> <a title="AJG_Vol.112.No1 page 94" href="http://viewer.zmags.com/publication/f9bebf6b?page=94"> independently by two reviewers using the Ne</a> <a title="AJG_Vol.112.No1 page 95" href="http://viewer.zmags.com/publication/f9bebf6b?page=95"> 68 Irvine et al. Table 1. Characteristic</a> <a title="AJG_Vol.112.No1 page 96" href="http://viewer.zmags.com/publication/f9bebf6b?page=96"> Celiac Disease in IBS 69 Table 1. Continu</a> <a title="AJG_Vol.112.No1 page 97" href="http://viewer.zmags.com/publication/f9bebf6b?page=97"> 70 Irvine et al. REVIEW Table 2. Pooled pr</a> <a title="AJG_Vol.112.No1 page 98" href="http://viewer.zmags.com/publication/f9bebf6b?page=98"> Celiac Disease in IBS 71 </a> <a title="AJG_Vol.112.No1 page 99" href="http://viewer.zmags.com/publication/f9bebf6b?page=99"> 72 Irvine et al. REVIEW Table 3. Pooled pr</a> <a title="AJG_Vol.112.No1 page 100" href="http://viewer.zmags.com/publication/f9bebf6b?page=100"> Celiac Disease in IBS 73 </a> <a title="AJG_Vol.112.No1 page 101" href="http://viewer.zmags.com/publication/f9bebf6b?page=101"> 74 Irvine et al. </a> <a title="AJG_Vol.112.No1 page 102" href="http://viewer.zmags.com/publication/f9bebf6b?page=102"> ACKNOWLEDGMENTS We are grateful to Dr Yuhong Yuan</a> <a title="AJG_Vol.112.No1 page 103" href="http://viewer.zmags.com/publication/f9bebf6b?page=103"> 76 Irvine et al. REVIEW 50. Rodrigo L, Bla</a> <a title="AJG_Vol.112.No1 page 104" href="http://viewer.zmags.com/publication/f9bebf6b?page=104"> CLINICAL AND SYSTEMATIC REVIEWS 77 CME</a> <a title="AJG_Vol.112.No1 page 105" href="http://viewer.zmags.com/publication/f9bebf6b?page=105"> CLINICAL AND SYSTEMATIC REVIEWS 78 C</a> <a title="AJG_Vol.112.No1 page 106" href="http://viewer.zmags.com/publication/f9bebf6b?page=106"> sies should be considered when assessing for celi</a> <a title="AJG_Vol.112.No1 page 107" href="http://viewer.zmags.com/publication/f9bebf6b?page=107"> 80 Pardi Another report indicated an i</a> <a title="AJG_Vol.112.No1 page 108" href="http://viewer.zmags.com/publication/f9bebf6b?page=108"> Abnormal collagen metabolism Collagen typing stud</a> <a title="AJG_Vol.112.No1 page 109" href="http://viewer.zmags.com/publication/f9bebf6b?page=109"> 82 Pardi REVIEW make the diagnosis of MC i</a> <a title="AJG_Vol.112.No1 page 110" href="http://viewer.zmags.com/publication/f9bebf6b?page=110"> Stop NSAIDs and other drugs or dietary factors </a> <a title="AJG_Vol.112.No1 page 111" href="http://viewer.zmags.com/publication/f9bebf6b?page=111"> 84 Pardi REVIEW 28. Madisch A, Miehlke S</a> <a title="AJG_Vol.112.No1 page 112" href="http://viewer.zmags.com/publication/f9bebf6b?page=112"> 85. Osterholm MT, MacDonald KL, White KE et al.</a> <a title="AJG_Vol.112.No1 page 113" href="http://viewer.zmags.com/publication/f9bebf6b?page=113"> 86 CLINICAL AND SYSTEMATIC REVIEWS CME</a> <a title="AJG_Vol.112.No1 page 114" href="http://viewer.zmags.com/publication/f9bebf6b?page=114"> ORIGINAL CONTRIBUTIONS 87 see related e</a> <a title="AJG_Vol.112.No1 page 115" href="http://viewer.zmags.com/publication/f9bebf6b?page=115"> 88 Guthikonda et al. ESOPHAGUS knowledge e</a> <a title="AJG_Vol.112.No1 page 116" href="http://viewer.zmags.com/publication/f9bebf6b?page=116"> a 200 150 100 Number of surveillance visits</a> <a title="AJG_Vol.112.No1 page 117" href="http://viewer.zmags.com/publication/f9bebf6b?page=117"> 90 Guthikonda et al. ESOPHAGUS Table 1. Ba</a> <a title="AJG_Vol.112.No1 page 118" href="http://viewer.zmags.com/publication/f9bebf6b?page=118"> Recurrence After RFA for BE 91 Table 3. </a> <a title="AJG_Vol.112.No1 page 119" href="http://viewer.zmags.com/publication/f9bebf6b?page=119"> 92 Guthikonda et al. ESOPHAGUS Table 4. Un</a> <a title="AJG_Vol.112.No1 page 120" href="http://viewer.zmags.com/publication/f9bebf6b?page=120"> Proportion without invasive adenocarcinoma 1.00 </a> <a title="AJG_Vol.112.No1 page 121" href="http://viewer.zmags.com/publication/f9bebf6b?page=121"> 94 Guthikonda et al. ESOPHAGUS Study Highl</a> <a title="AJG_Vol.112.No1 page 122" href="http://viewer.zmags.com/publication/f9bebf6b?page=122"> ORIGINAL CONTRIBUTIONS 95 see related e</a> <a title="AJG_Vol.112.No1 page 123" href="http://viewer.zmags.com/publication/f9bebf6b?page=123"> 96 Targownik et al. STOMACH However, the p</a> <a title="AJG_Vol.112.No1 page 124" href="http://viewer.zmags.com/publication/f9bebf6b?page=124"> being defined as those voxels having a calculated</a> <a title="AJG_Vol.112.No1 page 125" href="http://viewer.zmags.com/publication/f9bebf6b?page=125"> 98 Targownik et al. STOMACH Table 3. Resul</a> <a title="AJG_Vol.112.No1 page 126" href="http://viewer.zmags.com/publication/f9bebf6b?page=126"> PPI Use Not Associated With Decreased Bone Streng</a> <a title="AJG_Vol.112.No1 page 127" href="http://viewer.zmags.com/publication/f9bebf6b?page=127"> 100 Targownik et al. STOMACH Overall, th</a> <a title="AJG_Vol.112.No1 page 128" href="http://viewer.zmags.com/publication/f9bebf6b?page=128"> 28. Heaney RP, Recker RR, Weaver CM. Absorbabilit</a> <a title="AJG_Vol.112.No1 page 129" href="http://viewer.zmags.com/publication/f9bebf6b?page=129"> 102 ORIGINAL CONTRIBUTIONS LIVER INTRODUCTION </a> <a title="AJG_Vol.112.No1 page 130" href="http://viewer.zmags.com/publication/f9bebf6b?page=130"> The pathogenesis of NAFLD is multi-facette</a> <a title="AJG_Vol.112.No1 page 131" href="http://viewer.zmags.com/publication/f9bebf6b?page=131"> 104 Feldman et al. LIVER The SNPs PNPLA3</a> <a title="AJG_Vol.112.No1 page 132" href="http://viewer.zmags.com/publication/f9bebf6b?page=132"> Lean Non-Alcoholic Fatty Liver Disease 105 </a> <a title="AJG_Vol.112.No1 page 133" href="http://viewer.zmags.com/publication/f9bebf6b?page=133"> 106 Feldman et al. LIVER Table 2. Prevalen</a> <a title="AJG_Vol.112.No1 page 134" href="http://viewer.zmags.com/publication/f9bebf6b?page=134"> Lean Non-Alcoholic Fatty Liver Disease 107 </a> <a title="AJG_Vol.112.No1 page 135" href="http://viewer.zmags.com/publication/f9bebf6b?page=135"> 108 Feldman et al. LIVER Table 3. Regressi</a> <a title="AJG_Vol.112.No1 page 136" href="http://viewer.zmags.com/publication/f9bebf6b?page=136"> calculation. This highlights the challenge faced </a> <a title="AJG_Vol.112.No1 page 137" href="http://viewer.zmags.com/publication/f9bebf6b?page=137"> 110 Feldman et al. LIVER 2. Pallayova M,</a> <a title="AJG_Vol.112.No1 page 138" href="http://viewer.zmags.com/publication/f9bebf6b?page=138"> EDITORIAL 111 see related article on p</a> <a title="AJG_Vol.112.No1 page 139" href="http://viewer.zmags.com/publication/f9bebf6b?page=139"> 112 Argo and Henry LIVER obese NAFLD, this</a> <a title="AJG_Vol.112.No1 page 140" href="http://viewer.zmags.com/publication/f9bebf6b?page=140"> Financial Support: None. Potential competing inte</a> <a title="AJG_Vol.112.No1 page 141" href="http://viewer.zmags.com/publication/f9bebf6b?page=141"> 114 ORIGINAL CONTRIBUTIONS see related</a> <a title="AJG_Vol.112.No1 page 142" href="http://viewer.zmags.com/publication/f9bebf6b?page=142"> of both hypothyroidism and PBC, patients with PBC</a> <a title="AJG_Vol.112.No1 page 143" href="http://viewer.zmags.com/publication/f9bebf6b?page=143"> 116 Floreani et al. LIVER Table 1. Clinica</a> <a title="AJG_Vol.112.No1 page 144" href="http://viewer.zmags.com/publication/f9bebf6b?page=144"> pensation events or the onset of HCC during the f</a> <a title="AJG_Vol.112.No1 page 145" href="http://viewer.zmags.com/publication/f9bebf6b?page=145"> 118 Floreani et al. LIVER Table 5. Multiva</a> <a title="AJG_Vol.112.No1 page 146" href="http://viewer.zmags.com/publication/f9bebf6b?page=146"> Study Highlights WHAT IS CURRENT KNOWLEDGE ✓ Pri</a> <a title="AJG_Vol.112.No1 page 147" href="http://viewer.zmags.com/publication/f9bebf6b?page=147"> 120 ORIGINAL CONTRIBUTIONS INFLAMMATORY BOWEL </a> <a title="AJG_Vol.112.No1 page 148" href="http://viewer.zmags.com/publication/f9bebf6b?page=148"> Evolution After Anti-TNF Discontinuation in IBD P</a> <a title="AJG_Vol.112.No1 page 149" href="http://viewer.zmags.com/publication/f9bebf6b?page=149"> 122 Casanova et al. (top-down strategy</a> <a title="AJG_Vol.112.No1 page 150" href="http://viewer.zmags.com/publication/f9bebf6b?page=150"> (included as a continuous variable), surgery beca</a> <a title="AJG_Vol.112.No1 page 151" href="http://viewer.zmags.com/publication/f9bebf6b?page=151"> 124 Casanova et al. INFLAMMATORY BOWEL DISE</a> <a title="AJG_Vol.112.No1 page 152" href="http://viewer.zmags.com/publication/f9bebf6b?page=152"> Evolution After Anti-TNF Discontinuation in IBD P</a> <a title="AJG_Vol.112.No1 page 153" href="http://viewer.zmags.com/publication/f9bebf6b?page=153"> 126 Casanova et al. a 1.0 Proportio</a> <a title="AJG_Vol.112.No1 page 154" href="http://viewer.zmags.com/publication/f9bebf6b?page=154"> 1.0 0.8 0.6 0.4 0.0 Time </a> <a title="AJG_Vol.112.No1 page 155" href="http://viewer.zmags.com/publication/f9bebf6b?page=155"> 128 Casanova et al. a 100 90 INFLAMM</a> <a title="AJG_Vol.112.No1 page 156" href="http://viewer.zmags.com/publication/f9bebf6b?page=156"> sion, whereas the reported risk of relapse in the</a> <a title="AJG_Vol.112.No1 page 157" href="http://viewer.zmags.com/publication/f9bebf6b?page=157"> 130 Casanova et al. INFLAMMATORY BOWEL DISE</a> <a title="AJG_Vol.112.No1 page 158" href="http://viewer.zmags.com/publication/f9bebf6b?page=158"> REFERENCES 1. Lichtenstein GR, Yan S, Bala M et </a> <a title="AJG_Vol.112.No1 page 159" href="http://viewer.zmags.com/publication/f9bebf6b?page=159"> 132 ORIGINAL CONTRIBUTIONS FUNCTIONAL GI DISOR</a> <a title="AJG_Vol.112.No1 page 160" href="http://viewer.zmags.com/publication/f9bebf6b?page=160"> different diagnostic categories: (i) postprandial</a> <a title="AJG_Vol.112.No1 page 161" href="http://viewer.zmags.com/publication/f9bebf6b?page=161"> Stepwise distensions Liquid meal Time 2 min </a> <a title="AJG_Vol.112.No1 page 162" href="http://viewer.zmags.com/publication/f9bebf6b?page=162"> a 100 80 Frequency (%) 60 40 20 0 PD</a> <a title="AJG_Vol.112.No1 page 163" href="http://viewer.zmags.com/publication/f9bebf6b?page=163"> 136 Vanheel et al. a 100 Prevalence </a> <a title="AJG_Vol.112.No1 page 164" href="http://viewer.zmags.com/publication/f9bebf6b?page=164"> Pathophysiology of Rome III FD 137 Table</a> <a title="AJG_Vol.112.No1 page 165" href="http://viewer.zmags.com/publication/f9bebf6b?page=165"> 138 Vanheel et al. FUNCTIONAL GI DISORDERS </a> <a title="AJG_Vol.112.No1 page 166" href="http://viewer.zmags.com/publication/f9bebf6b?page=166"> as it aimed at decreasing the overlap group throu</a> <a title="AJG_Vol.112.No1 page 167" href="http://viewer.zmags.com/publication/f9bebf6b?page=167"> 140 Vanheel et al. FUNCTIONAL GI DISORDERS </a> <a title="AJG_Vol.112.No1 page 168" href="http://viewer.zmags.com/publication/f9bebf6b?page=168"> EDITORIAL 141 see related article on p</a> <a title="AJG_Vol.112.No1 page 169" href="http://viewer.zmags.com/publication/f9bebf6b?page=169"> 142 Talley FUNCTIONAL GI DISORDERS induced</a> <a title="AJG_Vol.112.No1 page 170" href="http://viewer.zmags.com/publication/f9bebf6b?page=170"> increased duodenal eosinophils and early satiety </a> <a title="AJG_Vol.112.No1 page 171" href="http://viewer.zmags.com/publication/f9bebf6b?page=171"> 144 Talley FUNCTIONAL GI DISORDERS 23. Lie</a> <a title="AJG_Vol.112.No1 page 172" href="http://viewer.zmags.com/publication/f9bebf6b?page=172"> ORIGINAL CONTRIBUTIONS 145 see related</a> <a title="AJG_Vol.112.No1 page 173" href="http://viewer.zmags.com/publication/f9bebf6b?page=173"> 146 Ringel-Kulka et al. FUNCTIONAL GI DISOR</a> <a title="AJG_Vol.112.No1 page 174" href="http://viewer.zmags.com/publication/f9bebf6b?page=174"> Study design: Screening Placebo run-in Intervent</a> <a title="AJG_Vol.112.No1 page 175" href="http://viewer.zmags.com/publication/f9bebf6b?page=175"> 148 Ringel-Kulka et al. procedure was </a> <a title="AJG_Vol.112.No1 page 176" href="http://viewer.zmags.com/publication/f9bebf6b?page=176"> Mean symptom severity B. infantis 35624 in Non-P</a> <a title="AJG_Vol.112.No1 page 177" href="http://viewer.zmags.com/publication/f9bebf6b?page=177"> 150 Ringel-Kulka et al. FUNCTIONAL GI DISOR</a> <a title="AJG_Vol.112.No1 page 178" href="http://viewer.zmags.com/publication/f9bebf6b?page=178"> and/or interpreting data: Y.R., T.R.K., and J.M.;</a> <a title="AJG_Vol.112.No1 page 179" href="http://viewer.zmags.com/publication/f9bebf6b?page=179"> 152 ORIGINAL CONTRIBUTIONS see related</a> <a title="AJG_Vol.112.No1 page 180" href="http://viewer.zmags.com/publication/f9bebf6b?page=180"> evaluated for adolescents with IBS. Most CBT prot</a> <a title="AJG_Vol.112.No1 page 181" href="http://viewer.zmags.com/publication/f9bebf6b?page=181"> 154 Bonnert et al. FUNCTIONAL GI DISORDERS </a> <a title="AJG_Vol.112.No1 page 182" href="http://viewer.zmags.com/publication/f9bebf6b?page=182"> Internet-CBT for Adolescents With IBS: RCT 15</a> <a title="AJG_Vol.112.No1 page 183" href="http://viewer.zmags.com/publication/f9bebf6b?page=183"> 156 Bonnert et al. Adolescent treatment</a> <a title="AJG_Vol.112.No1 page 184" href="http://viewer.zmags.com/publication/f9bebf6b?page=184"> Internet-CBT for Adolescents With IBS: RCT 15</a> <a title="AJG_Vol.112.No1 page 185" href="http://viewer.zmags.com/publication/f9bebf6b?page=185"> 158 Bonnert et al. GI DISORDERS FUNCTIONAL </a> <a title="AJG_Vol.112.No1 page 186" href="http://viewer.zmags.com/publication/f9bebf6b?page=186"> Internet-CBT for Adolescents With IBS: RCT 15</a> <a title="AJG_Vol.112.No1 page 187" href="http://viewer.zmags.com/publication/f9bebf6b?page=187"> 160 Bonnert et al. FUNCTIONAL GI DISORDERS </a> <a title="AJG_Vol.112.No1 page 188" href="http://viewer.zmags.com/publication/f9bebf6b?page=188"> Foundation, the Samariten Foundation, the Värksta</a> <a title="AJG_Vol.112.No1 page 189" href="http://viewer.zmags.com/publication/f9bebf6b?page=189"> 162 Bonnert et al. FUNCTIONAL GI DISORDERS </a> <a title="AJG_Vol.112.No1 page 190" href="http://viewer.zmags.com/publication/f9bebf6b?page=190"> ORIGINAL CONTRIBUTIONS 163 see related </a> <a title="AJG_Vol.112.No1 page 191" href="http://viewer.zmags.com/publication/f9bebf6b?page=191"> 164 Nagata et al. for pedunculated and</a> <a title="AJG_Vol.112.No1 page 192" href="http://viewer.zmags.com/publication/f9bebf6b?page=192"> bowel preparation solution (PEG-C) (16,17), was u</a> <a title="AJG_Vol.112.No1 page 193" href="http://viewer.zmags.com/publication/f9bebf6b?page=193"> 166 Nagata et al. COLON/SMALL BOWEL ficien</a> <a title="AJG_Vol.112.No1 page 194" href="http://viewer.zmags.com/publication/f9bebf6b?page=194"> Japanese National CT Colonography Trial (JANCT) </a> <a title="AJG_Vol.112.No1 page 195" href="http://viewer.zmags.com/publication/f9bebf6b?page=195"> 168 Nagata et al. COLON/SMALL BOWEL Table </a> <a title="AJG_Vol.112.No1 page 196" href="http://viewer.zmags.com/publication/f9bebf6b?page=196"> Japanese National CT Colonography Trial (JANCT) </a> <a title="AJG_Vol.112.No1 page 197" href="http://viewer.zmags.com/publication/f9bebf6b?page=197"> 170 Nagata et al. COLON/SMALL BOWEL formit</a> <a title="AJG_Vol.112.No1 page 198" href="http://viewer.zmags.com/publication/f9bebf6b?page=198"> Study Highlights WHAT IS CURRENT KNOWLEDGE ✓ Com</a> <a title="AJG_Vol.112.No1 page 199" href="http://viewer.zmags.com/publication/f9bebf6b?page=199"> 172 ORIGINAL CONTRIBUTIONS </a> <a title="AJG_Vol.112.No1 page 200" href="http://viewer.zmags.com/publication/f9bebf6b?page=200"> progression (2). The ability to diagnose PC in as</a> <a title="AJG_Vol.112.No1 page 201" href="http://viewer.zmags.com/publication/f9bebf6b?page=201"> 174 Kaur et al. PANCREAS AND BILIARY TRACT </a> <a title="AJG_Vol.112.No1 page 202" href="http://viewer.zmags.com/publication/f9bebf6b?page=202"> per patient. Statistical analysis for the diagnos</a> <a title="AJG_Vol.112.No1 page 203" href="http://viewer.zmags.com/publication/f9bebf6b?page=203"> 176 Kaur et al. levels in response to </a> <a title="AJG_Vol.112.No1 page 204" href="http://viewer.zmags.com/publication/f9bebf6b?page=204"> a d Sample set used for asses</a> <a title="AJG_Vol.112.No1 page 205" href="http://viewer.zmags.com/publication/f9bebf6b?page=205"> 178 Kaur et al. PANCREAS AND BILIARY TRACT </a> <a title="AJG_Vol.112.No1 page 206" href="http://viewer.zmags.com/publication/f9bebf6b?page=206"> MUC5AC and CA19-9 in Early Diagnosis of Pancreati</a> <a title="AJG_Vol.112.No1 page 207" href="http://viewer.zmags.com/publication/f9bebf6b?page=207"> 180 Kaur et al. a c </a> <a title="AJG_Vol.112.No1 page 208" href="http://viewer.zmags.com/publication/f9bebf6b?page=208"> MUC5AC and CA19-9 in Early Diagnosis of Pancreati</a> <a title="AJG_Vol.112.No1 page 209" href="http://viewer.zmags.com/publication/f9bebf6b?page=209"> 182 Kaur et al. PANCREAS AND BILIARY TRACT </a> <a title="AJG_Vol.112.No1 page 210" href="http://viewer.zmags.com/publication/f9bebf6b?page=210"> Surinder K. Batra was involved in study design, i</a> <a title="AJG_Vol.112.No1 page 211" href="http://viewer.zmags.com/publication/f9bebf6b?page=211"> 184 LETTERS TO THE EDITOR Pathogenes</a> <a title="AJG_Vol.112.No1 page 212" href="http://viewer.zmags.com/publication/f9bebf6b?page=212"> several case-studies that show an association bet</a> <a title="AJG_Vol.112.No1 page 213" href="http://viewer.zmags.com/publication/f9bebf6b?page=213"> 186 Letters to the Editor It represents</a> <a title="AJG_Vol.112.No1 page 214" href="http://viewer.zmags.com/publication/f9bebf6b?page=214"> linaclotide, lubiprostone, and prucalopride prove</a> <a title="AJG_Vol.112.No1 page 215" href="http://viewer.zmags.com/publication/f9bebf6b?page=215"> 188 Letters to the Editor </a> <a title="AJG_Vol.112.No1 page 216" href="http://viewer.zmags.com/publication/f9bebf6b?page=216"> developing a complex model on the basis of these </a> <a title="AJG_Vol.112.No1 page 217" href="http://viewer.zmags.com/publication/f9bebf6b?page=217"> 190 Letters to the Editor ab </a> <a title="AJG_Vol.112.No1 page 218" href="http://viewer.zmags.com/publication/f9bebf6b?page=218"> lance colonoscopy in ulcerative colitis? L</a> <a title="AJG_Vol.112.No1 page 219" href="http://viewer.zmags.com/publication/f9bebf6b?page=219"> 192 ANNOUNCEMENTS CALENDAR OF COURSE</a> <a title="AJG_Vol.112.No1 page 220" href="http://viewer.zmags.com/publication/f9bebf6b?page=220"> ERRATA, CORRIGENDA AND RETRACTIONS 193 Er</a> <a title="AJG_Vol.112.No1 page 221" href="http://viewer.zmags.com/publication/f9bebf6b?page=221"> CLASSIFIEDS Opportunities for two Gastroenterolog</a> <a title="AJG_Vol.112.No1 page 222" href="http://viewer.zmags.com/publication/f9bebf6b?page=222"> NORWICH GI ASSOCIATES Professional Care with Pers</a> <a title="AJG_Vol.112.No1 page 223" href="http://viewer.zmags.com/publication/f9bebf6b?page=223"> University of Pittsburgh | UPMC Div</a> <a title="AJG_Vol.112.No1 page 224" href="http://viewer.zmags.com/publication/f9bebf6b?page=224"> IMPORTANT SAFETY INFORMATION SUPREP® Bowel Prep K</a> <a title="AJG_Vol.112.No1 page 225" href="http://viewer.zmags.com/publication/f9bebf6b?page=225"> #1 MOST PRESCRIBED, BRANDED BOWEL PREP KIT1 </a>